Connection lost
Server error
Mylan Pharmaceuticals, Inc. v. Tommy G. Thompson, Secretary of Health and Human Services, Bernard A. Schwetz, D.V.M., ph.d, Acting Principal Deputy Commissioner, U.S. Food and Drug Administration, and U.S. Food and Drug Administration, and Bristol-Myers Squibb Company Case Brief
Why Top Law Students (And Those Aspiring to Be) Use LSD+ Briefs
Let's be real, law school is a marathon. Our exclusive Flash-to-Full case system is designed by Harvard Law School and MIT grads to match your pace: Quick summaries when you're slammed, detailed analysis when you need to go deep. Only LSD+ offers this kind of flexibility to genuinely fit your study flow.
Adaptive Case Views
Toggle between Flash, Standard, and Expanded. Get what you need, when you need it.
Exam-Ready IRAC Format
We deliver the precise structure professors look for in exam answers.
Complex Cases, Clarified
We break down dense legal reasoning into something digestible, helping you grasp core concepts.
Case Brief Summary & Legal Analysis
tl;dr: A generic drug maker sued a patent holder to force the “delisting” of a recently issued patent from the FDA’s Orange Book. The court held that no such private cause of action exists under patent law or the Hatch-Waxman Act.
Legal Significance: This case established that generic drug manufacturers cannot sue pioneer drug companies directly to delist an allegedly improperly listed patent. The proper forum to challenge the patent is through a standard patent infringement or declaratory judgment action on grounds of invalidity or non-infringement.
Mylan Pharmaceuticals, Inc. v. Tommy G. Thompson, Secretary of Health and Human Services, Bernard A. Schwetz, D.V.M., ph.d, Acting Principal Deputy Commissioner, U.S. Food and Drug Administration, and U.S. Food and Drug Administration, and Bristol-Myers Squibb Company Law School Study Guide
Use this case brief structure for your own legal analysis. Focus on the IRAC methodology to excel in law school exams and cold calls.
Case Facts & Court Holding
Key Facts & Case Background
Bristol-Myers Squibb (Bristol) held a patent for the anxiety drug BuSpar, which was listed in the FDA’s “Orange Book.” Mylan Pharmaceuticals, Inc. (Mylan), a generic manufacturer, prepared to market its generic version of BuSpar upon the expiration of Bristol’s patent. Approximately eleven hours before the patent expired, Bristol obtained a new patent (‘365 patent) claiming a method of using a metabolite of BuSpar and submitted it to the FDA for listing in the Orange Book. Under the Hatch-Waxman Act, this new listing automatically stayed the FDA’s approval of Mylan’s generic drug for up to 30 months. Instead of filing a Paragraph IV certification to challenge the new patent’s validity or assert non-infringement—the standard statutory procedure—Mylan filed suit against Bristol and the FDA. Mylan sought a declaratory judgment that the ‘365 patent was improperly listed and a preliminary injunction compelling Bristol to delist the patent and the FDA to approve Mylan’s application. The district court granted the injunction, and Bristol appealed.
Court Holding & Legal Precedent
Issue: Does the Hatch-Waxman Act or general patent law provide a generic drug manufacturer with a cause of action to seek a declaratory judgment forcing a patentee to delist a patent from the FDA’s Orange Book?
No. The court reversed the district court’s preliminary injunction. Mylan’s claim to Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum
IRAC Legal Analysis
Complete IRAC Analysis for Higher Grades
IRAC (Issue, Rule, Analysis, Conclusion) is the exact format professors want to see in your exam answers. Our exclusive Flash-to-Full briefs combine holding, analysis, and rule statements formatted to match what A+ students produce in exams. These structured briefs help reinforce the essential legal reasoning patterns expected in law school.
Legal Issue
Does the Hatch-Waxman Act or general patent law provide a generic drug manufacturer with a cause of action to seek a declaratory judgment forcing a patentee to delist a patent from the FDA’s Orange Book?
Conclusion
This decision clarifies the procedural boundaries of Hatch-Waxman litigation, affirming that a Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis
Legal Rule
An allegation that a patent was improperly listed in the FDA's Orange Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dol
Legal Analysis
The Federal Circuit analyzed Mylan's claim through the lens of the Declaratory Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum. Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum. Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum. Lorem ipsum dolor sit amet, consectetur adipi
Flash-to-Full Case Opinions
Flash Summary
- A generic drug manufacturer has no private right of action to